Hurdles Faced By Healthcare Providers in Titrating Phenytoin Dosage in Long-Term Care

      Medications are associated with development of adverse drug events (ADEs), some more than others, due to alteration in pharmacokinetics and dynamics with age. Phenytoin efficacy and toxicity relate to drug levels, interaction with cytochrome P450, hepatic function and albumin levels; phenytoin is largely protein bound. Our case illustrates the difficulties in dosing phenytoin in a long-term care resident.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect